Objective-Low high-density lipoprotein cholesterol (HDL-C) is associated with cardiometabolic pathologies. In this study, we investigate the biological pathways and individual genes behind low HDL-C by integrating results from 3 highthroughput data sources: adipose tissue transcriptomics, HDL lipidomics, and dense marker genotypes from Finnish individuals with low or high HDL-C (n=450). Approach and Results-In the pathway analysis of genetic data, we demonstrate that genetic variants within inflammatory pathways were enriched among low HDL-C associated single-nucleotide polymorphisms, and the expression of these pathways upregulated in the adipose tissue of low HDL-C subjects. The lipidomic analysis highlighted the change in HDL particle quality toward putatively more inflammatory and less vasoprotective state in subjects with low HDL-C, as evidenced by their decreased antioxidative plasmalogen contents. We show that the focal point of these inflammatory pathways seems to be the human leukocyte antigen region with its low HDL-associated alleles also associating with more abundant local transcript levels in adipose tissue, increased plasma vascular cell adhesion molecule 1 levels, and decreased HDL particle plasmalogen contents, markers of adipose tissue inflammation, vascular inflammation, and HDL antioxidative potential, respectively. In a population-based look-up of the inflammatory pathway single-nucleotide polymorphisms in a large Finnish cohorts (n=11 211), no association of the human leukocyte antigen region was detected for HDL-C as quantitative trait, but with extreme HDL-C phenotypes, implying the presence of low or high HDL genes in addition to the population-genomewide association studies-identified HDL genes. Conclusions-Our study highlights the role of inflammation with a genetic component in subjects with low HDL-C and identifies novel cis-expression quantitative trait loci variants in human leukocyte antigen region to be associated with low HDL-C. 3 Low HDL-C concentration is also a component of atherogenic dyslipidemia, the lipid profile associated with obesity and type 2 diabetes mellitus, which contributes to the escalating burden of coronary artery disease globally. The genetic basis of low HDL-C levels has remained elusive, despite intensive research for decades because of the complexity of HDL particles that are the most malleable lipid particles in circulation.
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A low level of plasma high-density lipoprotein cholesterol (HDL-C) is a well-established risk marker for coronary artery disease, 1,2 the leading cause of death worldwide. 3 Low HDL-C concentration is also a component of atherogenic dyslipidemia, the lipid profile associated with obesity and type 2 diabetes mellitus, which contributes to the escalating burden of coronary artery disease globally. The genetic basis of low HDL-C levels has remained elusive, despite intensive research for decades because of the complexity of HDL particles that are the most malleable lipid particles in circulation.
During the last 5 years, genome-wide association (GWA) studies have identified around 40 genome-wide significant loci for HDL-C levels. 4 Many of the genes identified in the GWA studies were known from the candidate gene era, such as CETP or ABCA1, but several novel loci, like GALNT2, with no previous link to lipoprotein biology have emerged. 5 The large GWA studies have been conducted mainly on normolipidemic individuals, and even if the effects of many variants identified in genetic population studies have also been demonstrated in more extreme groups, 6 it has been argued that studying the genetic architecture of individuals with diagnosed dyslipidemia may uncover additional novel lipid loci. 7 It has been shown, for instance, that multiple rare variants from well-established HDL-C candidate genes were enriched in individuals with low HDL-C levels 8 and hypertriglyceridemia, 7 and a pathway-based analysis strategy identified biologically plausible candidate genes for HDL-C. 9 The demand for a more comprehensive view of low HDL-C biology calls for functional analyses of the variants identified. First, the putative genetic variants associated with low HDL-C levels form the basis of such analysis, and because their effects are often attributed to genotype dependent gene expression, transcriptome analysis from relevant tissues is desirable. Although the routine collection of visceral fat and liver biopsies remains unfeasible, studying transcript profiles between individuals with low and high HDL-C in adipose tissue represents a relevant way to gain insight into the functional role of the low HDL-C associated variants because adipose tissue is involved in plasma lipid metabolism through its contribution to HDL biogenesis 10 and its secretion of adipokines, a process boosted by HDL particles. 11 Second, although decreased plasma HDL-C concentration is strongly associated with impaired atheroprotection, a more profound understanding of the low HDL-C state also demands an answer to the question: Is the composition of HDL particles different between subjects with low and high HDL-C levels, and if it is, are these differences genetically regulated, possibly even by the actual variants associated with low HDL-C? Differences in HDL composition have already been observed in diseases, such as psoriasis, 12 uremia, 13 and infection, 14 for instance.
Although GWA and gene expression platforms facilitate the discovery of genetic variants predisposing to low HDL-C, lipidomics can assist in identifying compositional differences in the HDL particles between subjects with low and high HDL-C levels. Lipidomics attempts to quantify every lipid species present in a particular tissue, and the advances in high-resolution mass spectrometry have guided our way in the identification of previously uncharacterized lipid species. 15 The lipid levels obtained from lipidomic analyses, representing an intermediate trait among disease phenotype, transcript, and associated genotype, open the potential to gain more detailed insights in disease pathogenesis, adding to the correlations between disease loci and affection status. 16, 17 Earlier lipidomic studies have mostly been performed from human plasma, 18 but such an approach has also proven suitable for extensive lipid characterization of lipoproteins. 19 An integrated study combining multiple sources of highthroughput data calls for more extensive analytic tools than single association tests. Pathway analysis is an essential tool for such analyses, as it is based on the principle that genes do not work in isolation; functionally related genes may have fairly small yet consistent changes in their expression patterns. 20 Pathway analysis has later been adopted in GWA studies, 9, 21 validating pathways involved in lipid metabolism, 22 for instance.
In the present study, we have investigated the differences in genetic architecture, adipose tissue and leukocyte gene expression and lipidomic profiles from isolated plasma HDL particles between individuals with low HDL-C and high HDL-C levels in carefully characterized patients, with a welldefined clinical phenotype. We have approached the challenge related to data analysis from multiple omics by first studying each of the 3 omics at a time to discover biological pathways relevant to low HDL-C phenotype. We then searched for common biological motifs in these 3 data sets, and from the common motifs we have then sifted individual genetic variants contributing to low plasma HDL-C concentration. Finally, we integrate the data sets into combined analysis of genomics, transcriptomics, and lipidomics.
Patients and Methods
Patients and Methods are available in the online-only Supplement.
Results
The genomic, transcriptomic, and lipidomic profiles for this study were obtained from Finnish patients, including individuals with familial low HDL-C or high HDL-C. Low HDL-C was defined as HDL-C <10 th age-and sex-specific population percentile (n=227), and high HDL-C as HDL-C >90 th percentile (n=223) ( Table I in the online-only Data Supplement). Our extensive measurement panels combine genome-wide single-nucleotide polymorphism (SNP) panel with transcriptome analysis from the subcutaneous adipose tissue and lipidome analysis from plasma HDL particles (Figure 1 ). In our analysis strategy, we first study the canonical pathways behind low and high HDL-C group profile in each high-throughput domains, then search for common biological motifs across these domains, ultimately sifting single gene effects out from these pathways.
First, the genetic pathway analysis revealed that genes belonging to immune or inflammatory response-related pathways were overrepresented among the genetic markers associated with the low or high HDL-C affection status. The best associated canonical pathway from the IPA ontology (see Materials and methods) was interleukin-4 signaling (P=7×10 −5 , B-H P=1×10 ) pathways (Table II in the onlineonly Data Supplement) .
Second, gene expression analysis of subcutaneous adipose tissue from individuals with low or high HDL-C status uncovered that, when compared to the subjects with high HDL-C, there was a downregulation of mitochondrial pathways, titled "mitochondrial dysfunction" (P=3×10 −15 , B-H P=8×10 −13 ) and "oxidative phosphorylation" (P=6×10 −15 , B-H P=8×10 −13 ) in subjects with low HDL-C levels ( Figure 2 ; Table  III in the online-only Data Supplement). Interestingly, the most significant pathways upregulated in the adipose tissue of low HDL subjects were again related to inflammation ( Figure  2 ; Table IV ) and because of their similar gene contents and relatedness with inflammation and the immune system, processes tightly coupled to HDL function, 23 we decided to introduce a broader group of genes, the "combined inflammatory pathway" encompassing every gene belonging to any of the top 2 SNP-derived pathways (Table 1; Figure 2 ; Table V in the online-only Data Supplement) .
Third, the mass spectrometry analysis of HDL particle lipidome from subjects with low or high HDL-C concentrations convincingly indicated that there were not only differences in the quantity of HDL-C but also in HDL quality (Tables VI and  VII in 25 were reduced in the HDL particles of subjects with low HDL-C when compared with individuals with high HDL-C. In contrast, the most enriched lipid species in the HDL particles derived from subjects with low HDL-C were proinflammatory ceramides ( By showing that the HDL particles in individuals with low HDL-C are likely to be less atheroprotective because of their reduced antioxidative capacity owing to their lower plasmalogen contents, we thus provide evidence of a concomitant impairment in HDL quality and a decrease in HDL quantity in subjects with low HDL-C. To better reflect the interrelations of these omics, we created a lipidomics pathway from these plasmalogens, naming it "antioxidative pathway" (Table VIII in the online-only  Data Supplement) .
Next, we proceeded to a more integrated type of data analysis by looking for common biological motifs among genomics, transcriptomics, and lipidomics. The occurrence of the combined inflammatory pathway among the top pathways in both SNP and adipose tissue gene expression pathway analyses provided a biological link between genomics and transcriptomics, and we tested whether the genetic burden predisposing to low HDL-C influenced the expression of this pathway. The higher number of risk alleles for low HDL-C within the combined inflammatory pathway was indeed associated with increased expression of that pathway (β=0.64; We further studied whether these genetic variants within the combined inflammatory pathway have an effect on vascular inflammation and endothelial activation, both hallmarks of atherosclerosis. 26 Vascular adhesion molecules, such as vascular cell adhesion molecule 1 (VCAM1) and intercellular adhesion molecule 1 (ICAM1), slow circulating leukocytes down on the endothelial monolayer surface to promote their tissue migration and are potent mediators of acute inflammation. Compelling evidence on their involvement in atherosclerosis exists. 27, 28 In our previous study, 29 we demonstrated that the serum concentrations of the soluble forms of these adhesion molecules (sVCAM1, sICAM1), good markers of their endothelial expression, 30 were elevated in subjects with low HDL-C. Also, E-selectin and C-reactive protein measurements were available for 61 individuals (of these, fat biopsies were available for 30 individuals) from this study. Consistent with the expression and lipidomic analyses, the VCAM1 concentrations were also elevated individuals having large number of low HDL-C associated risk alleles (Figure III D and Table IX C in the online-only Data Supplement), implicating that some variants of the combined inflammatory pathway have an effect on vascular inflammation.
Even if our discovery sample contains uniquely characterized individuals with familial low HDL, we also performed a population-based look-up for the SNPs of the combined inflammatory pathway. We conducted a meta-analysis across 5 large Finnish population cohorts (n=11 221) to study the effects of combined inflammatory pathway SNPs on HDL-C in general population. No association for any of the SNPs was detected in the analysis using HDL-C as a quantitative trait ( Table 2) . Because our discovery sample consists of individuals with familial low or high HDL-C with inclusion criteria based on population percentiles (<10 th and >90 th population percentile, respectively), we created a binary variable of the low or high HDL-C status in the Finnish cohorts in a similar fashion. The ratio indicates the proportion of genes regulated in the given pathway divided by the total number of genes in that pathway. B-H P value, P value calculated using the Benjamini-Hochberg correction. Pathways constituting the combined inflammatory pathway are shown. The canonical pathways are obtained from the Ingenuity Ontology (www.ingenuity.com). §The reference allele is underlined.
The allelic OR is calculated by treating the reference allele as exposure to low HDL-C and other allele as nonexposure. If reference allele is the low HDL-C associated allele, then OR>1. Only the most significant SNP from each haploblock was included in genetic risk score calculation †The critical P value for 5% significance is 0.001 using Bonferroni correction for 3×14=42 tests. ‡P value smaller than the critical P value using Bonferroni correction.
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In addition to the <10 th and >90 th low or high HDL-C percentile criteria applied in the discovery sample, we also used <25 th or >75 th (n=6132) as well as <5 th or >95 th (n=2267) percentiles as low or high HDL-C criteria in the Finnish cohorts. Similar to quantitative HDL-C, virtually no significant hits were detected for any of the 14 combined inflammatory pathway SNP effects on low or high HDL-C status at the <25 th or >75 th percentile criteria, whereas at <10 th or >90 th percentile, the effects started to emerge for a subset of SNPs, leading to even more pronounced effects at <5 th or >95 th percentile (odds ratio, 2.05; P=7×10 -4 ; Bonferroni P=0.02 for human leukocyte antigen [HLA] region rs3135338). For these 6 SNPs, located mostly in the HLA region, not only did the probability values get more significant toward extremes of the phenotypic spectrum but also the effects per se became larger ( Table 2) .
Because the HLA region was the genomic area with strongest associations with low HDL-C within the combined inflammatory pathway, we next searched for functional evidence for these variants. The availability of adipose tissue biopsies from individuals with familial low HDL-C enabled us to search for loci displaying cis-expression quantitative trait loci (eQTL) properties. Within the HLA region, we found 2 significant, dose-dependent cis-eQTL associations: rs241437 in the 10 th intron of TAP2 and rs9272143 between HLA-DRB1 and HLA-DQA1 (Table X in the online-only Data Supplement). Individuals having the minor allele of rs9272143 showed decreased expression of HLA-DRB1 (P=4×10 -7 ) and the likelihood of having low HDL-C status (P=0.00019) ( Figure 3A and 3B, Table IX A in the online-only Data Supplement), whereas carriers of the minor allele of rs241437 showed increased expression of TAP2 in the adipose tissue and were more likely to belong to the low HDL-C group (P=0.00012) in a dosedependent manner (P=2×10 -6 ) ( Figure 3E and 3F; Table IX B in the online-only Data Supplement). We also verified the eQTL of TAP2 rs241437 in blood leukocytes (P=4×10 -27 ) in a Finnish population data set (n=513) with both dense marker genotype data and blood leukocyte expression data available ( Figure 3G ; Table IX B in the online-only Data Supplement). We also tested whether these SNPs within the HLA region were associated with compositional differences in HDL particles because the deeper analysis of the HDL lipidome highlighted the reduction of antioxidative lipid species in subjects with low HDL-C levels. Although TAP2 rs241437 did not reach statistical significance (P=0.08) ( Figure 3H , Table IX B in the online-only Data Supplement), the presence of the minor allele of HLA-DRB1 rs9272143 was associated with downregulation of the antioxidative pathway in (P=0.03) ( Figure 3C , Table IX A in the online-only Data Supplement), implying an impaired HDL particle quality of in subjects with the minor allele carriers. We finally tested whether these SNPs within the HLA region also influence inflammatory parameters. The minor allele of HLA-DRB1 rs9272143 was dose-dependently associated with elevated sVCAM1 (β= −0.38; P=8×10 -4 ; Figure 3D ; Table IX A in the online-only Data Supplement), and to some extent TAP2 rs241437 as well (P=0.03, Figure 3I , Table IX B in the online-only Data Supplement), suggesting a potential role of this genomic region in vascular inflammation. No associations for sICAM1, nor E-selectin and C-reactive protein were detected, which were also measured in our previous study (Table XI in the online-only Data Supplement). Because HLA-DRA rs3135338 showed the most significant SNP in the population look-up of the HLA SNPs, we also tested its association on inflammatory parameters. After testing, the effects of the most significant eQTL SNP, HLA-DRB1 rs9272143, remained superior to rs3135338 (Table XI in 
Discussion
In this study, we have combined genomics, transcriptomics, and lipidomics to study the molecular basis of low HDL-C Earlier studies strongly link lipids with inflammation. We previously showed that the expression of a gene cluster in leukocytes harboring inflammatory genes was associated with blood lipids in a general population, 31 and HDL itself has been described as a potent anti-inflammatory agent. HDL particles have been shown to suppress proinflammatory chemokine production, 32 repress the expression of cellular adhesion molecules, 33 and inhibit inflammation inducing transcription factors, such as nuclear factor-κB and AP-1. 34 Our current study, on the contrary, suggests that rather than being a controller of the inflammatory milieu of the body, the HDL particles themselves may be subject to regulation by inflammatory signals, as pointed out by the low HDL-C associated SNPs also showing eQTLs. This is in agreement with previous studies showing that inflammation impairs reverse cholesterol transport, 35, 36 reduces phospholipid contents, and increases serum amyloid A-contents of HDL particles, 36 and that macrophages in subjects with low HDL-C display a proinflammatory gene expression pattern. 37 Because the low HDL-C associated SNPs in inflammatory genes were also associated with their increased transcript abundance in adipose tissue and vascular inflammation markers, such as VCAM1, it is likely that the effects of these variants on low HDL-C are mediated through aforementioned inflammatory processes, although a direct genetic effect on low HDL-C is also possible (Figure 4) .
In our study, we not only show that the quantity of HDL-C is different between individuals with low or high HDL-C but also its quality. The lipidomic analyses indicate that the lipid species enriched in the HDL particles derived from subjects with high HDL-C were ether bond containing phosphatidylethanolamines, that is, plasmalogens and lysophosphatidylcholines, whereas a single ceramide (d:18:1/20:1) and different types of triglycerides were overrepresented in the HDL particles derived from subjects with low HDL-C, in line with our previous study. 19 Ether lipids have, interestingly, been shown to be diminished in children that go on to develop type 1 diabetes mellitus. 38 Although the amount of plasmalogens has not been reported to causally contribute to low HDL-C, more evidence regarding the link between plasmalogens and atherosclerosis exists. Oxidation of LDL promotes atherogenesis, 39 and because plasmalogens have been shown to inhibit both cholesterol 24 and LDL 40, 41 oxidation, an impaired antioxidative capacity of HDL particles can be one of the potential antiatherogenic mechanisms in subjects with low HDL-C (Figure 4) . The amount of plasmalogens in the HDL particles, designated as the "antioxidative pathway," was associated with genetic variants within the inflammatory pathway, indicating a potential genetic component for the quality of HDL particles.
Within the inflammation related pathways that were enriched with low HDL-C associated SNPs, we found rs241437 within TAP2 and rs9272143 within HLA-DRB1 to have significant adipose tissue cis-eQTLs, in addition to being associated with plasma low HDL-C levels. HLA-DRB1 is a subunit of the MHC II complex, which triggers the inflammatory response by antigen presentation, and TAP2 is involved in the transport of antigenic peptides from the cytoplasm into the endoplasmic reticulum, 42 working in concert with HLA-derived peptides. The HLA region has been associated with >500 diseases affecting every major organ system, 43 majority of them classified as autoimmune disease, although population stratification might have led to discovery of false-positive findings attributed to potential problems in selection of controls. However, robust associations in HLA and TAP2 have also been reported for common diseases, including type 1 diabetes mellitus, 44, 45 ankylosing spondylitis, 46, 47 rheumatoid arthritis, 48, 49 and celiac disease. This is the first study to report the low HDL-C association of these genes. In our study, population stratification is unlikely to cause false-positive results attributed to the fact that our samples were collected from the homogenous Finnish population. Moreover, we have controlled the population structure in the discovery data set by the region of origin of the controls, and in the population look-up dataset, the analyses were adjusted for the first 3 principal components with no evidence of population stratification. The allele associated with increased transcript abundance and sVCAM1 in both genes was also the one associated with low HDL-C, implying a parallel HLA mediated increase in both adipose tissue and vascular inflammation in subjects with low HDL-C.
The effects of the HLA SNPs on sVCAM1 provide further biological plausibility on our findings and link them directly to vascular inflammation. During acute inflammatory response, VCAM1 is one of the first molecules to be expressed on endothelial surface to slow the rolling leukocytes down. The causal role of VCAM1 on atherosclerosis has been demonstrated in mice, in which a 12-fold VCAM1 protein reduction led to decreased atherosclerosis development, 27 whereas human studies have suggested VCAM1 involvement in atherosclerotic processes through mononuclear leukocyte recruitment. 28 Our results, thus, suggest that the low HDL-C associated risk alleles of TAP2 rs241437 and HLA-DRB1 rs9272143 may also be involved in the potentially proatherogenic vascular inflammation through VCAM1 activation. There is a chance that the effect of these alleles on elevated sVCAM1 may be a result of their HDL-C lowering effect, as HDL has been shown to inhibit VCAM1 expression in vitro 50 ( Figure 4 ), but they may also influence sVCAM1 in an HDL-independent manner. The fact that these variants of the combined inflammatory pathway or the pathway itself did not associate with ICAM1 or C-reactive protein may be attributed to lack of power, but even if a true negative finding, such results are likely to be clinically meaningless, as earlier studies have demonstrated the dominance of VCAM1 over ICAM1 in atherosclerosis development, 27 and 2 large Mendelian randomization studies 51, 52 have provided compelling evidence against the causal relationship between C-reactive protein and coronary heart disease.
The foundation of our study lies in the careful selection of individuals with extreme phenotypes; the cases with low HDL-C and the hypercontrols with high HDL-C, although this study design may also be argued as a potential limitation of the study. However, we intentionally chose this approach, as it allows us to study maximal differences and to minimize the effect of confounding factors. Studies using such selected genotyping method are reported to have more power in detecting rare variants with large effects, 53 but simulations using this approach have also proved its efficiency in discovering common alleles. 54 It is noteworthy that the SNPs within the combined inflammatory pathway detected in the individuals with familial low HDL-C were not associated with HDL-C as a quantitative trait in the large Finnish population cohorts (n=11 221), when we performed the population look-up of the variants. Only after individuals with either low or high HDL-C, using the <25 th or >75 th , <10 th or >90 th , and <5 th or >95 th percentiles, were left in the analyses, 6 of the 14 associated SNPs did show a tendency of increased significance and effect size toward the more extreme phenotype. Our results, by no means, are at odds with the large population-based GWA studies on HDL-C as a quantitative trait, such as the >100 000 individuals study, 55 which is extremely well-powered to detect variants, even with very small effects. Our use of extremes in studying the genetic background of lipid traits simply provides a complementary, not alternative approach to the large population studies. The more stringent phenotype criteria resulting in more pronounced effects, especially for the HLA region, implies the existence of low or high HDL-C genes that might operate independent of the population GWAS-identified HDL-C genes, which is supported by the larger and more significant effects emerging for 6 of the 14 SNPs toward the extreme phenotypes in the population cohorts. Contrary to the hypothesis that selective genotyping facilitates the discovery of rare variants, the novel variants identified in our study were also common in the general population, belonging to neither low nor high HDL-C groups. The fact that the signals emerged only after rigorous selection criteria might imply the presence of external stimuli that through gene × gene 56 or gene × environment 57 interactions with the low or high HDL-C variants could influence HDL-C at the extreme ends of the phenotypic spectrum.
The limitations of this study include the smaller sample size of our discovery sample as compared with population level genetic meta-analyses. The study subjects, however, have been carefully selected based on a solid clinical phenotype, and the availability of mass spectrometry HDL particle lipidomics data and adipose tissue transcriptomics adds to the biological information obtained from the genetic analysis. As simulated by permutation analysis for 339 416 SNPs, the expected number of SNPs reaching higher significance than P=0.001 was 235, the same number observed in our analysis. Although our most strongly associated marker list used in the pathway analysis included several known lipid loci, it is also likely that the proportion of false-positive genes was relatively high in the pathway analysis for low HDL-C associated genetic markers. This, however, unlikely affects the result interpretation regarding the HLA region, as the most significant HLA cis-eQTL SNP also associated with elevated VCAM1 levels and lower HDL particle plasmalogen contents, thus providing further biological evidence to our findings, and in the Finnish population cohort look-up the effects of SNPs in HLA region increased in both magnitude and significance toward the extreme percentiles. Regarding gene expression analysis, because obesity is closely linked with impaired mitochondrial and amplified inflammatory gene expression in the adipose tissue, 58 we had to consider the possibility that these changes in adipose tissue transcriptome might be attributed to the modestly different body mass index (BMI) levels observed in the low and high HDL groups (Table I in the online-only Data Supplement). To exclude this alternative, we reanalyzed the expression data by setting equal BMI means to both high and low HDL-C groups and also studied the effects of BMI on individual probe intensities. The BMImatched pathway analysis yielded similar results for both upregulated in the low HDL-C and downregulated in the low HDL-C groups, and no probe intensity within the combined inflammatory pathway was influenced by BMI (Table V in the online-only Data Supplement), indicating that the differential expression of mitochondrial and inflammatory pathways in the low and high HDL-C groups seems to be BMI independent. In contrast, the fact that there was a significant difference in the plasma triglyceride levels between low HDL-C and high HDL-C groups (Table I in the online-only Data Supplement), and that the expression of 4 of 19 probes of the combined inflammatory pathway was significantly (P<0.05) associated with plasma triglyceride levels (Table V in the online-only Data Supplement) suggests that a considerable degree of phenotypic overlap between HDL-C and triglycerides exists, as reported in previous studies.
This study combining GWA, transcriptomic, and lipidomic data allows us to draw several conclusions. First, genes within inflammatory pathways are associated with plasma low HDL-C concentrations implying a potential role for inflammation contributing to low HDL-C levels. Second, there was an overexpression of genes within the inflammatory pathway in adipose tissue of subjects with low HDL-C. Third, individuals with low HDL-C displayed a significant reduction of antioxidative lipids in their HDL particles. Fourth, in a biologically consistent fashion, low HDL-C associated HLA variants were also associated with both increased expression of local transcripts in adipose tissue as a marker of adipose tissue inflammation, increased levels of VCAM1 in circulation as a marker of vascular inflammation, and compositional changes in HDL particles as indicated by their decreased plasmalogen contents. Fifth, none of the associations of the inflammatory genes could be seen for HDL-C as quantitative trait in the general population look-up, but the effects of the HLA region emerged only after individuals with extreme HDL-C values were selected for association analysis. These results suggest the existence of low or high HDL-C genes in addition to the well-established HDL-C genes, implying that as a phenotype, low HDL-C might lie in the gray zone between monogenic and polygenic inheritance. The integration of multiple sources of highthroughput data in this study has provided novel insights into low HDL-C, and such strategies might be useful in the future to understand the pathophysiology of other complex traits.
Supplement Material
Supplementary The fold change (low HDL-C / high HDL-C) indicates the mean expression of that probe in the low HDL-subjects divided by the mean expression of that probe in the high HDL-subjects. The expression values have been obtained from subcutaneous adipose tissue of the subjects. As indicated, the effect of BMI on gene expression was negligent, whereas there was some effect by triglycerides (TG).
Supplementary table VI. Lipid species whose concentration is increased in the HDL particles of subjects with low HDL-C concentrations as compared to subjects with high HDL-C The p-values represent significance from eQTL analyses. The critical p-value for 5 % significance is 0.001 using Bonferroni correction for 49 tests. *P-value more significant than the critical P-value using Bonferroni correction. The markers rs2395173 and rs9271055 are not shown in this Genetic risk score tertile of the 'combined inflammatory pathway' n=15 n=34 n=18 P = 6 x 10 -3
Supplementary methods

Example MS peak data for lipid profiling and quantification
Here is an example MS peak data from low HDL-C group (for the first compound in Supplementary table 6 Mean value from all samples in low HDL-C group = (4.60E-09+5.75E-09+8.09E-09+8.79E-09+8.56E-09+9.84E-09+8.85E-09+5.50E-09+4.07E-09+5.32E-09+8.035E-09+7.96E-09+7.74E-09+2.86E-092.24E-09+7.52E-09+7.17E-09+4.97E-09+7.25E-09+3.64E-09+6.70E-09+6.076E-09) /22
Mean value from all low HDL-C samples = 6. (4), a representative random sample of persons aged between 25 and 74 years is selected from the population of five geographical areas of Finland. The survey includes a mailed questionnaire and a clinical examination during which blood samples are collected. A total of 23,036 individuals participated in the cohorts, and gave written informed consent. The dense marker genotype data were available for 2,066 subjects selected as healthy controls for CAD-cases from another study. (5) is a prospective cohort study conducted at five university departments of medical schools in Finland (i.e., Turku, Helsinki, Kuopio, Tampere, and Oulu), with the objective to study the levels of cardiovascular risk factors in children and adolescents in different regions of the country. The first cross-sectional survey was conducted in 1980. Total sample size was 4,320 boys and girls in 6 age cohorts (aged 3, 6, 9, 12, 15 and 18). These subjects were randomly selected from the national register. A total of 3,596 subjects (83.2% of those invited) participated in the study in 1980. After that, several follow-up studies of this cohort have been conducted, the latest follow-up being performed in 2007, when the study subjects had reached the age of 30 to 45 years. In the latest follow-up in 2007 the total number of individuals examined was 2,204. 
YFS (Cardiovascular Risk of Young Finns Study). The YFS
